Clinical Trial Update: Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies [EARLY_Phase 1]

View source ↗

Summary

This clinical trial update describes an early-phase (Phase 1) study of LV009 injection for relapsed/refractory CD19-positive hematologic and lymphoid malignanci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• LV009

Snippet

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Conditions: Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Adult | EARLY_Phase 1 | Status: RECRUITING